Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Neubauer

Showing results (511-520 of 554) with videos related to

Pageof 56
Sort By:
Plos One|August 28, 2018
Rare gene deletions in genetic generalized and Rolandic epilepsiesKamel Jabbari, Dheeraj R Bobbili, Dennis Lal, et al.
Cancer Research|October 30, 2025
Multi-omics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic DiscoveryAleksandr Ianevski, Kristen Nader, Julia Nguyen, et al.
Leukemia|January 12, 2017
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|May 7, 2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibB Hanfstein, V Shlyakhto, M Lauseker, et al.
Nature Communications|June 9, 2019
Structural and functional consequences of the STAT5B<sup>N642H</sup> driver mutationElvin D de Araujo, Fettah Erdogan, Heidi A Neubauer, et al.
Journal of Medical Genetics|July 31, 2017
Heterogeneous contribution of microdeletions in the development of common generalised and focal epilepsiesEduardo Pérez-Palma, Ingo Helbig, Karl Martin Klein, et al.
Epileptic Disorders : International Epilepsy Journal with Videotape|July 21, 2016
Idiopathic focal epilepsies: the "lost tribe"Deb K Pal, Colin Ferrie, Laura Addis, et al.
Leukemia|October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CM C Müller, N Gattermann, T Lahaye, et al.
Leukemia|January 31, 2018
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Journal of Medicinal Chemistry|June 8, 2021
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic LeukemiaKrimo Toutah, Nabanita Nawar, Sanna Timonen, et al.
Pageof 56

Showing results (511-520 of 554) with videos related to

Sort By:
Pageof 56
Plos One|August 28, 2018
Rare gene deletions in genetic generalized and Rolandic epilepsiesKamel Jabbari, Dheeraj R Bobbili, Dennis Lal, et al.
Cancer Research|October 30, 2025
Multi-omics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic DiscoveryAleksandr Ianevski, Kristen Nader, Julia Nguyen, et al.
Leukemia|January 12, 2017
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|May 7, 2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibB Hanfstein, V Shlyakhto, M Lauseker, et al.
Nature Communications|June 9, 2019
Structural and functional consequences of the STAT5B<sup>N642H</sup> driver mutationElvin D de Araujo, Fettah Erdogan, Heidi A Neubauer, et al.
Journal of Medical Genetics|July 31, 2017
Heterogeneous contribution of microdeletions in the development of common generalised and focal epilepsiesEduardo Pérez-Palma, Ingo Helbig, Karl Martin Klein, et al.
Epileptic Disorders : International Epilepsy Journal with Videotape|July 21, 2016
Idiopathic focal epilepsies: the "lost tribe"Deb K Pal, Colin Ferrie, Laura Addis, et al.
Leukemia|October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CM C Müller, N Gattermann, T Lahaye, et al.
Leukemia|January 31, 2018
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Journal of Medicinal Chemistry|June 8, 2021
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic LeukemiaKrimo Toutah, Nabanita Nawar, Sanna Timonen, et al.
Pageof 56